Skip to main content
. 2020 Dec 21;46(4):774–782. doi: 10.1038/s41386-020-00935-x

Table 4.

Top-down selected baseline variables associated with trajectory class membership for patients treated with tDCS + placebo, escitalopram + sham tDCS, and placebo + sham tDCS.

Rapid vs. slow Rapid vs. no/minimal Slow vs. no/minimal
Predictor OR z PFDR OR z PFDR OR z PFDR
tDCS
  Treatment-resistant depression 0.75 (0.2–2.76) −0.43 0.667 2.58 (0.64–10.46) 1.33 0.454 1.94 (0.55–6.87) 1.03 0.454
  Anxiety 0.9 (0.8–1.01) −1.76 0.118 1.16 (1.01–1.33) 2.09 0.111 1.05 (0.92–1.19) 0.66 0.511
  Age 1.02 (0.98–1.07) 1.07 0.284 0.93 (0.88–0.99) −2.48 0.039 0.96 (0.9–1.01) −1.65 0.147
  Benzodiazepine use 0.21 (0.06–0.73) −2.47 0.039 1.56 (0.37–6.6) 0.61 0.545 0.33 (0.1–1.13) −1.76 0.117
  Depression severity 0.98 (0.83–1.15) −0.28 0.780 1.28 (1.07–1.52) 2.75 0.009 1.25 (1.07–1.46) 2.78 0.009
Escitalopram
  Treatment-resistant depression 0.64 (0.24–1.69) −0.90 0.391 2.39 (0.87–6.59) 1.68 0.279 1.53 (0.58–4.04) 0.86 0.391
  Anxiety 0.98 (0.9–1.06) −0.56 0.963 1 (0.91–1.1) 0.02 0.986 0.98 (0.89–1.07) −0.46 0.963
  Age 1.01 (0.97–1.04) 0.34 0.731 0.97 (0.93–1.01) −1.25 0.510 0.98 (0.94–1.02) −0.96 0.510
  Benzodiazepine use 1.49 (0.48–4.61) 0.69 0.487 1.54 (0.49–4.9) 0.74 0.487 2.3 (0.7–7.56) 1.37 0.487
  Depression severity 0.93 (0.82–1.06) −1.04 0.297 1.16 (1.01–1.33) 2.06 0.120 1.08 (0.95–1.23) 1.15 0.297
Placebo
  Treatment-resistant depression 0.18 (0.03–0.97) −1.99 0.138 2.05 (0.28–15.18) 0.70 0.484 0.37 (0.06–2.16) −1.10 0.404
  Anxiety 0.96 (0.85–1.07) −0.74 0.457 1.3 (1.08–1.56) 2.83 0.015 1.24 (1.04–1.49) 2.40 0.026
  Age 0.98 (0.93–1.03) −0.91 0.543 0.99 (0.92–1.06) −0.30 0.767 0.97 (0.91–1.03) −1.10 0.543
  Benzodiazepine use 4.77 (0.56–40.82) 1.43 0.154 7.05 (0.85–58.27) 1.81 0.105 33.65 (3.98–284.23) 3.23 0.003
  Depression severity 0.85 (0.7–1.04) −1.59 0.170 1.32 (1.04–1.69) 2.24 0.075 1.12 (0.9–1.4) 1.03 0.302

R reference category; depression severity as measured by HAM-D 17-items; boldface indicates significance after FDR correction; OR odds ratio with CI95% in parenthesis; significance of regression weights computed using Wald tests.